President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

Both Casgevy and Lyfgenia are highlighted in a recent Clarivate report among 13 potential “blockbuster and gamechanger” drugs to watch in 2024. Vertex's gene-editing therapy for sickle cell ...

The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...

The therapy was the first treatment to make it to market in the indication, closely followed by bluebird bio’s Lyfgenia (lovo-cel)—also a gene therapy. Less than six weeks later, Casgevy ...

The monthslong treatment Casgevy from Vertex Pharmaceuticals comes with a list price of $2.3 million. Bluebird Bio’s Lyfgenia is listed at $3.1 million. Neither includes the cost of care to stay ...

Since two gene therapies were approved for sickle cell disease in late 2023, only a handful of patients have started the expensive treatments.

CHOP doctors Thompson and Grupp have devoted their lives to improving the quality and length of life for children with sickle ...

The FDA recently approved two groundbreaking CRISPR-based gene therapies 💉 for curing Sickle Cell Disease (SCD): Casgevy - developed by Vertex Pharmaceuticals and CRISPR Therapeutics Lyfgenia ...

Story continues below this ad 4. Casgevy and Lyfgenia: In December 2023, the FDA approved two groundbreaking treatments, Casgevy and Lyfgenia, the first cell-based gene therapies to treat sickle cell ...